Skip to content

Effect of ayurvedic medicines on metabolic syndrome

Concept of dhatvagni and its applicability in dhatvagni vyaparajanya vikara vis a vis metabolic syndrome

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/03/012893
Enrollment
100
Registered
2018-03-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E889- Metabolic disorder, unspecified Health Condition 2: null- patients of metabolic syndrome

Interventions

Intervention1: Bhringaraj Bhavita Bhringaraj Vati: 4 vati OD(500mg of each) with Lukewarm water at Apana Kala (empty stomach at morning) for 8weeks Control Intervention1: Triphala Gugulu: 4 vati OD(50

Sponsors

IPGT RA GAU jamnagar
Lead Sponsor
IPGT RA GAU jamnagar
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients having age between 20 to 60 years According to the NCEP Adult Treatment Panel III guideline revised in 2005 the presence of any three of the following five factors are required for a diagnosis of metabolic syndrome 2 Abdominal obesity waist circumference more than 90 cm in men and more than 80 cm in women 3 Hypertriglyceridemia S Triglycerides level 150 to 600 mg dl 4 Low HDL cholesterol S HDL cholesterol less than 40 mg dl for men and less than 50 mg dl for women 5 Elevated blood pressure Systolic blood pressure 130 to 139 mmHg and or diastolic blood pressure 85 to 90 mmHg 6 Impaired fasting glucose Fasting plasma glucose 100 to 125mg dl

Exclusion criteria

Exclusion criteria: 1 Age below 20 and above 60 years 2 Patients suffering from diabetes mellitus hypertension and taking anti diabetic and antihypertensive or anti hyperlipidemic drugs 3 Systemic illness like Tuberculosis Carcinoma and Endocrine disorders like Kushing syndrome Hypothyroidism 4 Patient having the past history of MI & Unstable Angina 5 Patient having clinical features of congestive cardiac failure 6 Patient having the major renal or liver disorder

Design outcomes

Primary

MeasureTime frame
Patients will be selected and Metabolic syndrome will be examined on the basis of specially prepared proforma along with a detailed history Improvement will be assessed on the basis of subjective as well as objective criterias Fair and lovely color grading scalesTimepoint: 8 weeks

Secondary

MeasureTime frame
Patients will be selected and Metabolic syndrome will be examined on the basis of specially prepared proforma along with a detailed history Improvement will be assessed on the basis of subjective as well as objective criterias Fair and lovely color grading scalesTimepoint: 8 weeks

Countries

India

Contacts

Public ContactDr Arjun Singh Baghel

IPGT & RA

asbaghel2001@yahoo.com7984780397

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026